Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Beta-blockers and overall survival in men receiving ADT + systemic therapy for metastatic prostate cancer.

Syed Ali Mehdi, Baqir Jafry, Jennifer Collins et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17112

e17112 Background: Beta-adrenergic signaling has been implicated in prostate cancer progression. However, observational st...

AcTFirst: A phase 3 trial of <sup>225</sup> Ac-PSMA-617 plus ARPI versus standard of care in adults with PSMA-positive metastatic castration-resistant prostate cancer.

Alton Oliver Sartor, Louise Emmett, Karim Olivier Fizazi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5134

TPS5134 Background: In the VISION and PSMAfore trials, β-emitting radioligand therapy (RLT) with [ 177...

Complementary liquid and tissue NGS testing to identify actionable therapeutic targets missed by single-modality profiling: Insights from a blood-tissue pilot cohort analysis.

Shaheenah S. Dawood, Eunice Teo, Rania Khoury Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15081

e15081 Background: Comprehensive genomic profiling (CGP) is standard-of-care for identifying actionable mutations in advan...

Decline in credit score and excess mortality risk among cancer patients: Evidence from Washington State.

Scott David Ramsey, Catherine R. Fedorenko, Li Li et al. Jun 01, 2026 pp. 11037-11037 10.1200/jco.2026.44.16_suppl.11037

11037 Background: Patients experiencing bankruptcy following a cancer diagnosis have been shown to have increased mortalit...

InDuRanS: A randomized phase II trial on induction immunochemotherapy followed by surgery or chemoradiotherapy and consolidation durvalumab in stage III NSCLC.

Eleni Gkika, Cornelius Waller, Cas Dejonckheere et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8125

TPS8125 Background: The optimal local treatment strategy for patients with resectable or borderline resectable stage IIIA/...

Discharge trajectories and 30-day readmission risk in hospitalized breast cancer patients with malignant pleural effusion: A National Readmissions study.

Abdul Jabbar Sorathia, Aqsa Zoey Sorathia Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13104

e13104 Background: Malignant pleural effusion (MPE) is a common complication of advanced breast cancer and a frequent caus...

Refined temporal-to-frontal horn shunting for trapped temporal horn syndrome: Long-term outcomes and complication management in a two-center series of 53 patients.

Xiaohui Ren, Zairan Wang, Lin Sang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14037

e14037 Background: Trapped temporal horn syndrome (TTH) is a rare form of obstructive hydrocephalus that frequently occurs...

ctDNA as a complement to gene-expression–based site prediction to guide therapy in cancer of unknown primary: Results from Fudan CUP-001.

Xin Liu, Shiyu Jiang, Qianlan Yao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15049

e15049 Background: Cancer of unknown primary (CUP) remains a clinical challenge with poor outcomes under empiric chemother...

Baseline predictors of treatment response in the bounce back mind-body resiliency trial for AYA cancer survivors.

Lucy Finkelstein-Fox, Tara Pattilachan Menon, Zeba Ahmad et al. Jun 01, 2026 pp. 12101-12101 10.1200/jco.2026.44.16_suppl.12101

12101 Background: Mind-body interventions hold promise for improving coping and reducing psychological distress among adol...

A randomized phase II study of selinexor added to standard induction and consolidation chemotherapy in adults with acute myeloid leukemia (AML).

Timothy S. Pardee, Keri Renee Maher, Madelyn Burkart et al. Jun 01, 2026 pp. 6512-6512 10.1200/jco.2026.44.16_suppl.6512

6512 Background: Preclinical and early clinical data suggest that inhibition of nuclear export by the XPOI inhibitor selin...

Real-world outcomes of first-line enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Anna Svarna, Michael Liontos, Athanasios Michas et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16595

e16595 Background: Metastatic urothelial carcinoma (mUC) is associated with poor prognosis. The approval of enfortumab ved...

National trends and mortality burden of lung cancer with secondary brain and meningeal metastases among U.S. adults aged ≥ 55 years: A retrospective National Inpatient Sample analysis from 1999 to 2024.

Muhammad Shehryar Ahmed, Umais Ahmed Shaikh, Syed Hassan Ali et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20695

e20695 Background: Lung cancer remains the leading cause of cancer-related mortality in the United States, with a substant...

Early-phase drug development in oncology: Geography of trials including US vs China.

Catarina Ribeiro Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23049

e23049 Background: Early-phase oncology drug development is predominantly driven by industry sponsors and spans multiple r...

Circulating kynurenine, tryptophan levels, and their ratio in lung cancer: A meta-analysis revealing subtype and outcome specific variations.

Navya Pillikunte Doddareddy, Zeeshan Solangi, Ranjith Sah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20548

e20548 Background: Dysregulation of the kynurenine pathway driven by indoleamine 2,3-dioxygenase-1 (IDO1), contributes to...

Fertility concerns, counseling, and preservation in AYA females with early-stage breast cancer: Chemotherapy receipt and timing.

Bolun Liu, Hazel Nichols, Jia Li et al. Jun 01, 2026 pp. 1564-1564 10.1200/jco.2026.44.16_suppl.1564

1564 Background: Adolescent and young adult (AYA) females with early-stage ER-negative and/or HER2-positive breast cancer...

Association of MET overexpression with patient outcomes in <i>EGFR</i> -mutant lung adenocarcinoma treated with first-line osimertinib.

Annie Lin, Kanan A. Shah, Jake Sharma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20757

e20757 Background: Activating EGFR mutations are present in up to 15-30% of lung adenocarcinoma patients, and are known ge...

Development and validation of a multidimensional cfDNA assay for cancer detection and tissue-of-origin prediction.

Hua Bao, Xiaoxi Chen, Haimeng Tang et al. Jun 01, 2026 pp. 10531-10531 10.1200/jco.2026.44.16_suppl.10531

10531 Background: Early detection remains a major unmet need in oncology, and multi-cancer early detection assays that ana...

ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).

Lauren Averett Byers, Byoung Chul Cho, Alissa Jamie Cooper et al. Jun 01, 2026 pp. 8008-8008 10.1200/jco.2026.44.16_suppl.8008

8008 Background: SCLC is an aggressive cancer with poor prognosis and limited treatment options. Seizure-related 6 homolog...

First-in-human novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies.

Lu Haiyang, Su Li, Yuxuan Song et al. Jun 01, 2026 pp. 7015-7015 10.1200/jco.2026.44.16_suppl.7015

7015 Background: Refractory/relapse (r/r) aggressive T-cell lymphomas have poor prognosis with 5-year PFS of 20~30%, meanw...

Cancer outcome among adolescents in Canada.

Samuel Sassine, Hallie Coltin, Maria Kondyli et al. Jun 01, 2026 pp. 10024-10024 10.1200/jco.2026.44.16_suppl.10024

10024 Background: Adolescents and young adults (AYA) with cancer, commonly defined as patients aged 15–39 years at diagnos...

Overall survival differences by treatment setting in older adults with classical Hodgkin lymphoma: A National Cancer Database analysis.

Nikki Verma, German Stemmelin, Sofía Rivarola et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19037

e19037 Background: Classical Hodgkin lymphoma (cHL) has high cure rates in younger patients but worse outcomes in older ad...

Long term outcomes of implantable central venous access devices (chemoports) in patients with malignancies: A prospective observational study.

Mayur M. Mane, Akash Shah, Rushit Shah Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23349

e23349 Background: Central venous access devices (CVADs) play a critical role in the delivery of long-term intravenous the...

INCA033890-303: A randomized, double-blind, phase 3 study of FOLFOX and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite-stable colorectal cancer.

Van K. Morris, Miguel Colon Donate, Jenny Seligmann et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3683

TPS3683 Background: Immune checkpoint inhibitors have demonstrated limited efficacy in the treatment of microsatellite sta...

Efficacy and safety of antibody-drug conjugates in advanced colorectal cancer: A systematic review and single-arm meta-analysis of early-phase clinical trials.

Tahmina Haque, Shreyashri Bandhya, Mahanaz Nabi Ansa et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15616

e15616 Background: Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide. Despite...

Maternal and neonatal complications associated with breast cancer systemic treatments: A VigiBase disproportionality analysis study.

Rayan Kabirian, Floriane Jochum, Elise Dumas et al. Jun 01, 2026 pp. 626-626 10.1200/jco.2026.44.16_suppl.626

626 Background: Pregnancy-associated breast cancer (PrBC) presents unique diagnostic and therapeutic challenges, with risi...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page